Lemaitre Vascular (LMAT) Stock Forecast & Price Target

Compare

225 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LMAT Analyst Ratings

Moderate Buy

2 Buy

3 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Lemaitre

Vascular

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LMAT Stock 12 Month Forecast

Average Price Target

$98.75

▲(13.17% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Lemaitre Vascular in the last 3 months. The average price target is $98.75 with a high forecast of $108.00 and a low forecast of $95.00. The average price target represents a 13.17% change from the last price of $87.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"$79","94":"$94","109":"$109","86.5":"$86.5","101.5":"$101.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$108.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$98.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,86.5,94,101.5,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.8,84.73846153846154,86.67692307692307,88.61538461538461,90.55384615384615,92.49230769230769,94.43076923076923,96.36923076923077,98.3076923076923,100.24615384615385,102.18461538461538,104.12307692307692,106.06153846153846,{"y":108,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.8,84.02692307692307,85.25384615384615,86.48076923076923,87.70769230769231,88.93461538461538,90.16153846153846,91.38846153846154,92.61538461538461,93.84230769230768,95.06923076923077,96.29615384615384,97.52307692307693,{"y":98.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.8,83.73846153846154,84.67692307692307,85.61538461538461,86.55384615384615,87.49230769230769,88.43076923076923,89.36923076923077,90.3076923076923,91.24615384615385,92.18461538461538,93.12307692307692,94.06153846153846,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":104.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.63,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.47,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.41,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$108.00

Average Price Target$98.75

Lowest Price Target$95.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Nathan Treybeck

Wells Fargo

$87→$93

Hold

6.58%

Upside

Reiterated

12/12/25

Wells Fargo Sticks to Their Hold Rating for Lemaitre Vascular (LMAT)

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

11/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), MBX Biosciences, Inc. (NASDAQ: MBX) and Lemaitre Vascular (NASDAQ: LMAT)

Frank Takkinen

Lake Street

$110

Buy

26.06%

Upside

Reiterated

11/07/25

Lake Street Sticks to Their Buy Rating for Lemaitre Vascular (LMAT)

James Sidoti

Sidoti

$120

Buy

37.52%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM), Lemaitre Vascular (NASDAQ: LMAT) and Shattuck Labs (NASDAQ: STTK)

Michael Petusky

Barrington

$95

Buy

8.87%

Upside

Reiterated

11/07/25

LeMaitre Vascular's Strong Financial Performance and Growth Prospects Justify Buy Rating and OUTPERFORM Status

Brett Fishbin

KeyBanc

―

Hold

―

Reiterated

11/07/25

Analysts Are Neutral on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI)

Kyle Bauser

Roth MKM

$108

Buy

23.77%

Upside

Initiated

11/07/25

Lemaitre Vascular (LMAT) Has a New Rating from Roth MKMWe are resuming coverage of LMAT with a Buy rating and $108 price target.

Ross Osborn

Cantor Fitzgerald

$95

Hold

8.87%

Upside

Reiterated

08/11/25

Cantor Fitzgerald Sticks to Their Hold Rating for Lemaitre Vascular (LMAT)Cantor Fitzgerald analyst Ross Osborn reiterated a Neutral rating and $95.00 price target on LeMaitre Vascular (NASDAQ: LMAT).

Daniel Stauder

Citizens JMP

$113

Buy

29.50%

Upside

Reiterated

07/28/25

Citizens JMP Remains a Buy on Lemaitre Vascular (LMAT)

Rick Wise

Stifel Nicolaus

$115

Buy

31.79%

Upside

Reiterated

05/02/25

Lemaitre Vascular (LMAT) Gets a Buy from Stifel Nicolaus

Unknown Analyst

Jefferies

Not Ranked

Jefferies

―

Hold

―

Reiterated

05/02/25

We maintain our Hold rating on LMAT.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Nathan Treybeck

Wells Fargo

$87→$93

Hold

6.58%

Upside

Reiterated

12/12/25

Wells Fargo Sticks to Their Hold Rating for Lemaitre Vascular (LMAT)

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

11/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), MBX Biosciences, Inc. (NASDAQ: MBX) and Lemaitre Vascular (NASDAQ: LMAT)

Frank Takkinen

Lake Street

$110

Buy

26.06%

Upside

Reiterated

11/07/25

Lake Street Sticks to Their Buy Rating for Lemaitre Vascular (LMAT)

James Sidoti

Sidoti

$120

Buy

37.52%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM), Lemaitre Vascular (NASDAQ: LMAT) and Shattuck Labs (NASDAQ: STTK)

Michael Petusky

Barrington

$95

Buy

8.87%

Upside

Reiterated

11/07/25

LeMaitre Vascular's Strong Financial Performance and Growth Prospects Justify Buy Rating and OUTPERFORM Status

Brett Fishbin

KeyBanc

―

Hold

―

Reiterated

11/07/25

Analysts Are Neutral on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI)

Kyle Bauser

Roth MKM

$108

Buy

23.77%

Upside

Initiated

11/07/25

Lemaitre Vascular (LMAT) Has a New Rating from Roth MKMWe are resuming coverage of LMAT with a Buy rating and $108 price target.

Ross Osborn

Cantor Fitzgerald

$95

Hold

8.87%

Upside

Reiterated

08/11/25

Daniel Stauder

Citizens JMP

$113

Buy

29.50%

Upside

Reiterated

07/28/25

Citizens JMP Remains a Buy on Lemaitre Vascular (LMAT)

Rick Wise

Stifel Nicolaus

$115

Buy

31.79%

Upside

Reiterated

05/02/25

Lemaitre Vascular (LMAT) Gets a Buy from Stifel Nicolaus

Unknown Analyst

Jefferies

Not Ranked

Jefferies

―

Hold

―

Reiterated

05/02/25

We maintain our Hold rating on LMAT.

Stocks with the Highest Top Analyst Consensus in the Sector

Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lemaitre Vascular

1 Month

xxx

Success Rate

17/34 ratings generated profit

Average Return

+2.02%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.02% per trade.

3 Months

xxx

Success Rate

18/34 ratings generated profit

Average Return

+4.34%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +4.34% per trade.

1 Year

Michael PetuskyBarrington

Success Rate

17/34 ratings generated profit

Average Return

+17.20%

reiterated a buy rating 2 months ago

Copying Michael Petusky's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +17.20% per trade.

2 Years

xxx

Success Rate

20/34 ratings generated profit

Average Return

+27.89%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of +27.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LMAT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LMAT has received 8 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. LMAT average Analyst price target in the past 3 months is 98.75.

Each month's total comprises the sum of three months' worth of ratings.

LMAT Financial Forecast

LMAT Earnings Forecast

Next quarter’s earnings estimate for LMAT is $0.66 with a range of $0.63 to $0.68. The previous quarter’s EPS was $0.75. LMAT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year LMAT has Performed in-line its overall industry.

LMAT Sales Forecast

Next quarter’s sales forecast for LMAT is $62.98M with a range of $61.80M to $64.60M. The previous quarter’s sales results were $61.05M. LMAT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year LMAT has Performed in-line its overall industry.

LMAT Stock Forecast FAQ

What is LMAT’s average 12-month price target, according to analysts?

Based on analyst ratings, Lemaitre Vascular’s 12-month average price target is 98.75.

What is LMAT’s upside potential, based on the analysts’ average price target?

Lemaitre Vascular has 13.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LMAT a Buy, Sell or Hold?

Lemaitre Vascular has a consensus rating of Moderate Buy which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.

What is Lemaitre Vascular’s price target?

The average price target for Lemaitre Vascular is 98.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $108.00 ,the lowest forecast is $95.00. The average price target represents 13.17% Increase from the current price of $87.26.

What do analysts say about Lemaitre Vascular?

Lemaitre Vascular’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of LMAT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Lemaitre Vascular (LMAT) Stock Forecast & Price Target

LMAT Analyst Ratings

LMAT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Lemaitre Vascular

LMAT Analyst Recommendation Trends

LMAT Financial Forecast

LMAT Earnings Forecast

LMAT Sales Forecast

LMAT Stock Forecast FAQ

Detailed List of Analyst Forecasts